16 recruiting, 7 unknown, 6 not yet recruiting, 5 completed. 26 Phase 2, 13 Phase 1, 2 Not applicable, 2 Phase 3.
Follow Small Cell Lung Cancer Extensive Stage: new trials by email Literature Review of Small Cell Lung Cancer Extensive Stage trials Research Report on Small Cell Lung Cancer Extensive Stage
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 152 | 2026-11-01 | 2026-10-22 |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer DSP-0390, Atezolizumab - Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | Phase 1 | Recruiting | Washington University School of Medicine | 20 | 2026-08-03 | 2026-08-04 |
| The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition - Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only) | Not applicable | Recruiting | University of Colorado, Boulder | 250 | 2026-05-04 | 2026-06-09 |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Gocatamig, I-DXd, Atezolizumab - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 170 | 2026-01-29 | 2026-10-20 |
| Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR - Small Cell Lung Cancer Extensive Stage, Brain Metastases | Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 105 | 2025-10-28 | 2026-08-17 |
| A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059) Small Cell Lung Cancer Extensive Stage | Not yet recruiting | Yong Fang | 100 | 2025-08-01 | 2025-07-08 | |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy sintilimab combined with anlotinib - Small Cell Lung Cancer Extensive Stage, Resistance to Immunotherapy | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 25 | 2025-07-01 | 2025-06-15 |
| A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer MHB088C for Injection, Topotecan, Irinotecan - Small Cell Lung Cancer Extensive Stage | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 450 | 2025-06-04 | 2025-06-18 |
| Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC α-PD-L1/4-1BB DLL3 CAR-T (BHP01) - Small Cell Lung Cancer Extensive Stage | Phase 1 | Recruiting | Sichuan University | 30 | 2025-04-03 | 2026-07-21 |
| Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer. radiotherapy, immunechemotherapy - Small Cell Lung Cancer Extensive Stage | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 64 | 2025-03-01 | 2025-02-28 |
| Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial Small Cell Lung Cancer Extensive Stage, ELDERLY PEOPLE | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 29 | 2025-02-01 | 2025-02-13 | |
| A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer Apatinib, Adebrelimab, Etoposide Injection - Small Cell Lung Cancer Extensive Stage | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 34 | 2025-01-25 | 2025-01-22 |
| Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC Irinotecan liposome (II) combined with adebrelimab and carboplatin, etoposide combined with adebrelimab and carboplatin - Small Cell Lung Cancer Extensive Stage | Phase 2 | Recruiting | Guangzhou Institute of Respiratory Disease | 120 | 2025-01-01 | 2024-12-18 |
| Liposomal Irinotecan and Apatinib in ES-SCLC Liposomal Irinotecan and Apatinib - Small Cell Lung Cancer Extensive Stage | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 30 | 2024-12-28 | 2024-12-27 |
| Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) Adebrelimab, Chemotherapy, low dose radiotherapy - Small Cell Lung Cancer Extensive Stage | Phase 2 | Recruiting | Sichuan University | 202 | 2024-12-23 | 2026-02-09 |
| Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer JS004, Toripalimab, Etoposide - Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | Phase 2 | Completed | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2024-11-18 | 2026-10-15 |
| PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer PD-L1 inhibitor combined with apatinib - Small Cell Lung Cancer Extensive Stage | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 40 | 2024-07-14 | 2025-05-28 |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients quaratusugene ozeplasmid, atezolizumab - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | Genprex, Inc. | 62 | 2024-05-09 | 2026-09-11 |
Showing 20 of 41. Sign in to see all of them.
Small Cell Lung Carcinoma (15) · Lung Neoplasms (3) · Carcinoma, Merkel Cell (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Small Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Liver Neoplasms (1)
Neoplasms (20) · Neoplasms by Site (20) · Lung Diseases (18) · Respiratory Tract Diseases (18) · Respiratory Tract Neoplasms (18) · Thoracic Neoplasms (18) · Bronchial Neoplasms (17) · Carcinoma, Bronchogenic (17) · Lung Neoplasms (15) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (5) · Carcinoma (4) · Genital Diseases (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3)
Etoposide (9) · Carboplatin (8) · atezolizumab (7) · apatinib (4) · pembrolizumab (4) · durvalumab (3) · Drug Therapy (2) · Immune Checkpoint Inhibitors (2) · Immunotherapy (2) · Paclitaxel (2) · Platinum (2) · Radiotherapy (2) · Topotecan (2) · irinotecan sucrosofate (2) · sintilimab (2)
Intergroupe Francophone de Cancerologie Thoracique (2) · Sichuan University (2) · Aktis Oncology, Inc. (1) · Ariceum Therapeutics GmbH (1) · Burzynski Research Institute (1) · First Affiliated Hospital of Wannan Medical College (1) · Fudan University (1) · Fujian Cancer Hospital (1) · Fundación GECP (1) · Genprex, Inc. (1) · Georgetown University (1) · Guangzhou Institute of Respiratory Disease (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hebei Medical University Fourth Hospital (1) · Henan Cancer Hospital (1)
China (18) · United States (14) · France (4) · Germany (4) · Spain (4) · Australia (3) · Greece (2) · Hungary (2) · Italy (2) · Poland (2) · South Korea (2) · Argentina (1) · Austria (1) · Bulgaria (1) · Canada (1)
Alberto A Chiappori, MD (1) · Chengzhi Zhou, Doctor (1) · Chul Kim, MD (1) · Ece Cali Daylan, MD, PhD (1) · Farastuk Bozorgmehr, Dr. med. (1) · Guangyuan Lou (1) · Haitao Wang (1) · Hiroaki Akamatsu, M.D. (1) · Jie Wang, doctor (1) · Jun Zhao (1) · Junliang Cai, MD (1) · Kazuhiko Nakagawa, M.D., Ph.D. (1) · Laura A Petrillo, MD (1) · Lin Wu (1)
PMID 32616557, PMID 33569214, PMID 34589918, PMID 34590034, PMID 36153496, PMID 39462179, PMID 39897044, PMID 39938469, PMID 42424047, PMID 42482749
2025 (1), R01CA300028 (1)